Fig. 7

Pharmacological treatment. a, b Pharmacological treatment in vitro. DU145 cells were treated with MCTP-39 at the indicated concentrations for 72 h. Panel a shows western blot data using the indicated antibodies. The position of a molecular marker is shown; uncropped images are provided in Supplementary Figure 6. b depicts colony forming assays showing quantification (top) and representative images (bottom). Shown are representative data from 3 independent experiments, each done in triplicate. Error bars represent the standard deviation (s.d.) from the mean; p-values were calculated using a two-tailed Student's t-test. c–f Pharmacological treatment in vivo. DU145 cells (5 × 10⁶ cells) were engrafted subcutaneously into male nude mouse hosts. After 1 week of growth, the tumor-bearing mice were randomized by cage to the vehicle (black) or MCTP-39 (red) treatment groups and treated with 10 mg/kg with MCTP-39 (or vehicle only) for up to 3 months. Tumor volume was monitored using calipers and calculated using the formula [Volume = (width)² x length/2]. Total mice analyzed for vehicle were 14 and for MCTP-39-treatment were 15 in two independent experiments. c Tumor volume. Two-way analysis of variance (ANOVA) was used to calculate the significance (p-value) of the difference between the vehicle and treatment group; ***p < 0.001 and ****p < 0.0001. d Representative tumors collected at at the time of euthanasia. e Western blot showing 2 examples from vehicle (lanes 1, 2) and MCTP-39 (lanes 3, 4) treated tumors using the indicated antibodies (total n = 4/group). The position of a molecular marker is shown; uncropped images are provided in Supplementary Figure 6. f Representative immunostaining for NSD2 and H3k36me3 from vehicle and MCTP-39 treated mice (n = 4/group). Scale bars represent 50 μ